Champions Oncology Names New CEO

Champions Oncology, a provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025.

Brainin, who has served on Champions’ Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017. Morris will transition to the role of Executive Chair on August 25, supporting the leadership transition while remaining actively involved in the company’s strategic initiatives.

“I want to thank Ronnie for his outstanding leadership and vision since 2017, and I am thrilled he will continue to play an integral role as Executive Chair,” said Joel Ackerman, Chairman of the Board, who will transition to a Director role. “As we expand beyond our core CRO services into a robust data offering, Rob’s expertise and track record of driving growth in innovative life sciences businesses make him the ideal leader to guide Champions through its next chapter.”

About Rob Brainin

Brainin brings more than 25 years of experience in life sciences and technology, with a proven ability to scale and grow businesses built on cutting-edge science and data capabilities. He most recently served as Chief Business Officer at Veracyte, an oncology diagnostics company, and previously as CEO of Genuity Science, a company focused on genomics, data, and therapeutic discovery.

“I am honored and excited to join Champions at such a pivotal time,” said Brainin. “The strength of Champions’ core CRO services provides a tremendous foundation to expand our emerging data platform and advance the pipeline of our discovery therapeutics subsidiary, Corellia AI. I look forward to working alongside this talented team to build on the company’s momentum and create value for our customers, employees, and shareholders.”